V
Valen E. Johnson
Researcher at Texas A&M University
Publications - 160
Citations - 10887
Valen E. Johnson is an academic researcher from Texas A&M University. The author has contributed to research in topics: Bayesian probability & Bayes factor. The author has an hindex of 43, co-authored 155 publications receiving 9541 citations. Previous affiliations of Valen E. Johnson include University of North Carolina at Chapel Hill & Lanzhou University.
Papers
More filters
Posted ContentDOI
A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome
Fan Gao,Xuedong Pan,Elissa B. Dodd-Eaton,Carlos Christian Vera Recio,Jasmina Bojadzieva,Phuong L. Mai,Kristin Zelley,Valen E. Johnson,Valen E. Johnson,Valen E. Johnson,Valen E. Johnson,Valen E. Johnson,Valen E. Johnson,Danielle Braun,Kim E. Nichols,Judy Garber,Sharon A. Savage,Louise C. Strong,Wenyi Wang +18 more
TL;DR: Famdenovo is developed to predict DNM status (DNM or familial mutation (FM) of deleterious autosomal dominant germline mutations for any syndrome and may serve as a foundation for future studies evaluating how new deleteriously mutations can be established in the germline, such as those in TP53.
Proceedings ArticleDOI
Segmentation and analysis of emission-computed-tomography images
TL;DR: In this paper, a statistical model for reconstruction of emission computed tomography (ECT) images is proposed, which is parameterized in terms of quantities of direct physiological significance, rather than only using grey-level voxel values.
Journal ArticleDOI
Longitudinal relationship between inflammatory markers and patient-reported symptom severity during induction therapy for multiple myeloma.
Mary H. Sailors,Xin Shelley Wang,Ping Liu,Valen E. Johnson,James M. Reuben,Evan N. Cohen,Loretta A. Williams,Tito R. Mendoza,Charles S. Cleeland +8 more
TL;DR: In this paper, the authors investigated the association between the trajectory of symptom onset and the duration of therapy-related symptoms in multiple myeloma patients undergoing induction therapy and found that MM patients with induction therapy experience both disease-and therapyrelated symptoms.
Journal ArticleDOI
Predictive value of baseline serum MIP-1α and CRP on symptom burden and tumor response to induction therapy in patients with multiple myeloma.
Charles S. Cleeland,Xin Shelley Wang,Sheeba K. Thomas,Ping Liu,Mary H. Sailors,Tito R. Mendoza,James M. Reuben,Evan N. Cohen,Katherine Ramsey Gilmore,Venus M Ilagan,Loretta A. Williams,Valen E. Johnson +11 more
TL;DR: Macrophage inflammatory protein-1α is a growth factor for human multiple myeloma (MM) cells and its presence provides pathophysiological evidence of the development of lytic bone lesions in MM.